GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Cash Receipts from Fees and Commissions

Ultimovacs ASA (OSL:ULTI) Cash Receipts from Fees and Commissions


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


Ultimovacs ASA (OSL:ULTI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Cash Receipts from Fees and Commissions
Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.